Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Lymphocyte function-associated antigen 3 (LFA-3) – Cluster of differentiation 2 (CD2) complex is a critical mediator of the immune response, formed by the interaction between LFA-3 (also known as CD58) and its receptor, CD2 (UniProt: P19235, P06729). LFA-3 is widely expressed on the surface of antigen-presenting cells, endothelial cells, and epithelial cells, while CD2 is primarily found on T lymphocytes and natural killer (NK) cells (PubMed: 10438934). This interaction facilitates stable cell-cell adhesion and provides essential costimulatory signals that lower the threshold for T cell receptor (TCR) activation, promoting T cell proliferation and cytokine production (PubMed: 1633953). In autoimmune and inflammatory conditions, such as chronic plaque psoriasis, this pathway is overactive, leading to the sustained activation of memory-effector T cells (StatPearls: NBK548582). Therapeutic targeting of this complex, most notably with the fusion protein alefacept, aims to disrupt this costimulatory signal and selectively deplete the pathogenic memory T cell population (DrugBank: DB00028). By binding to CD2, these therapies can effectively reduce inflammatory symptoms while maintaining a degree of overall immune competence compared to broader immunosuppressants.
Alefacept, a fusion protein consisting of the extracellular CD2-binding portion of LFA-3 linked to the Fc portion of human IgG1, binds to CD2 on T cells (DrugBank: DB00028). This action blocks the interaction between LFA-3 and CD2, thereby inhibiting T cell activation and proliferation. Additionally, the Fc portion of the drug interacts with FcγRIII (CD16) on NK cells to induce apoptosis of memory-effector T cells (CD45RO+), which are the primary drivers of chronic plaque psoriasis (PubMed: 12648212).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphocyte function-associated antigen 3 (LFA-3) – Cluster of differentiation 2 (CD2) complex (LFA-3 – CD2 complex).